Detalhe da pesquisa
1.
Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation.
Support Care Cancer
; 32(1): 53, 2023 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38129530
2.
2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents.
Support Care Cancer
; 32(1): 45, 2023 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38114821
3.
Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic.
Support Care Cancer
; 26(4): 1151-1159, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29080920
4.
2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy.
Support Care Cancer
; 25(1): 277-288, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27443154
5.
2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents.
Support Care Cancer
; 25(1): 271-275, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27501965
6.
2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy.
Support Care Cancer
; 25(1): 289-294, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27510316
7.
Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy.
Cancer
; 122(15): 2418-25, 2016 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27176138
8.
Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
Oncologist
; 21(4): 494-502, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27000465
9.
Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings-a meta-analysis.
Support Care Cancer
; 24(5): 1941-1954, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26476625
10.
Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies.
Support Care Cancer
; 24(4): 1517-25, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26370220
11.
Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline.
Pract Radiat Oncol
; 13(5): 393-412, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37294262
12.
Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting.
Support Care Cancer
; 20(3): 653-6, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22089429
13.
Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy.
Support Care Cancer
; 20(5): 1043-7, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21553313
14.
Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC).
Support Care Cancer
; 20(10): 2633-7, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22733373
15.
Erratum to: 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy.
Support Care Cancer
; 25(1): 295-296, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27624467
16.
Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study.
Support Care Cancer
; 20(7): 1471-8, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21822913
17.
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline.
J Clin Oncol
; 40(28): 3310-3322, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35816666
18.
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.
J Clin Oncol
; 40(28): 3323-3343, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35816668
19.
Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy.
Support Care Cancer
; 19(12): 2063-6, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21976035
20.
Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).
Support Care Cancer
; 19(9): 1297-302, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20623144